← Scisparc overview

Scisparc vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Scisparc Ltd (SPRC)

Q3 2026
▲4

SciSparc's AI and quantum pivot drives gains, Tourette drug advances

  • Agentic AI pivot opens new growth path SciSparc's board decided to target the agentic AI market and formed an AI and cybersecurity advisory board, while evaluating deals with several AI companies. This signals a strategic shift toward a high-growth tech sector, which can lift SPRC's price by attracting investors betting on a new business line beyond biotech.

    This is a new strategic direction that changes the company's story and investor appeal.

  • Quantum workflow validation sparks 70% surge NeuroThera Labs validated a quantum sampling workflow for clinical trial data on an S&P 500 company's platform, and SPRC shares jumped 70.5% to $9.09. The move shows investors are rewarding the quantum computing angle, though such sharp one-day spikes can fade without follow-through.

    This was the period's biggest price catalyst and shows how the quantum story is being received.

  • Tourette drug advances with Phase IIb and FDA orphan bid NeuroThera started a Phase IIb trial of SCI-110 for Tourette Syndrome at Hannover Medical School and is seeking FDA Orphan Drug Designation, hiring a government affairs firm. Progress on the core drug candidate supports SPRC's value by raising the odds of a future approved product.

    Clinical and regulatory progress on the main drug candidate is a fundamental value driver.

  • CliniQuantum reports 16.8-fold simulation speedup CliniQuantum, majority-owned by NeuroThera, reported a 16.8-fold speedup in quantum simulation on gene data using a GPU. The company itself notes this benchmark does not prove clinical value, so the news supports the tech narrative but is not yet a proven medical or revenue breakthrough.

    This is the latest quantum milestone that keeps the technology story alive for investors.

August 2026
▲4

SciSparc's AI and quantum pivot drives gains, Tourette drug advances

  • Agentic AI pivot opens new growth path SciSparc's board decided to target the agentic AI market and formed an AI and cybersecurity advisory board, while evaluating deals with several AI companies. This signals a strategic shift toward a high-growth tech sector, which can lift SPRC's price by attracting investors betting on a new business line beyond biotech.

    This is a new strategic direction that changes the company's story and investor appeal.

  • Quantum workflow validation sparks 70% surge NeuroThera Labs validated a quantum sampling workflow for clinical trial data on an S&P 500 company's platform, and SPRC shares jumped 70.5% to $9.09. The move shows investors are rewarding the quantum computing angle, though such sharp one-day spikes can fade without follow-through.

    This was the period's biggest price catalyst and shows how the quantum story is being received.

  • Tourette drug advances with Phase IIb and FDA orphan bid NeuroThera started a Phase IIb trial of SCI-110 for Tourette Syndrome at Hannover Medical School and is seeking FDA Orphan Drug Designation, hiring a government affairs firm. Progress on the core drug candidate supports SPRC's value by raising the odds of a future approved product.

    Clinical and regulatory progress on the main drug candidate is a fundamental value driver.

  • CliniQuantum reports 16.8-fold simulation speedup CliniQuantum, majority-owned by NeuroThera, reported a 16.8-fold speedup in quantum simulation on gene data using a GPU. The company itself notes this benchmark does not prove clinical value, so the news supports the tech narrative but is not yet a proven medical or revenue breakthrough.

    This is the latest quantum milestone that keeps the technology story alive for investors.

Latest
▲4

SciSparc's AI and quantum pivot drives gains, Tourette drug advances

  • Agentic AI pivot opens new growth path SciSparc's board decided to target the agentic AI market and formed an AI and cybersecurity advisory board, while evaluating deals with several AI companies. This signals a strategic shift toward a high-growth tech sector, which can lift SPRC's price by attracting investors betting on a new business line beyond biotech.

    This is a new strategic direction that changes the company's story and investor appeal.

  • Quantum workflow validation sparks 70% surge NeuroThera Labs validated a quantum sampling workflow for clinical trial data on an S&P 500 company's platform, and SPRC shares jumped 70.5% to $9.09. The move shows investors are rewarding the quantum computing angle, though such sharp one-day spikes can fade without follow-through.

    This was the period's biggest price catalyst and shows how the quantum story is being received.

  • Tourette drug advances with Phase IIb and FDA orphan bid NeuroThera started a Phase IIb trial of SCI-110 for Tourette Syndrome at Hannover Medical School and is seeking FDA Orphan Drug Designation, hiring a government affairs firm. Progress on the core drug candidate supports SPRC's value by raising the odds of a future approved product.

    Clinical and regulatory progress on the main drug candidate is a fundamental value driver.

  • CliniQuantum reports 16.8-fold simulation speedup CliniQuantum, majority-owned by NeuroThera, reported a 16.8-fold speedup in quantum simulation on gene data using a GPU. The company itself notes this benchmark does not prove clinical value, so the news supports the tech narrative but is not yet a proven medical or revenue breakthrough.

    This is the latest quantum milestone that keeps the technology story alive for investors.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 2026
▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

  • First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.

    The profit turnaround is the core fundamental change behind the stock's re-rating.

  • AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.

    A major global partnership is a new growth catalyst that directly lifts investor expectations.

  • New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.

    Regulatory progress on an existing product is a concrete new pipeline milestone.

  • Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.

    Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 2026
▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

  • First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.

    The profit turnaround is the core fundamental change behind the stock's re-rating.

  • AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.

    A major global partnership is a new growth catalyst that directly lifts investor expectations.

  • New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.

    Regulatory progress on an existing product is a concrete new pipeline milestone.

  • Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.

    Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest
▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

  • First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.

    The profit turnaround is the core fundamental change behind the stock's re-rating.

  • AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.

    A major global partnership is a new growth catalyst that directly lifts investor expectations.

  • New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.

    Regulatory progress on an existing product is a concrete new pipeline milestone.

  • Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.

    Institutional buying and supportive regulation are fresh demand and policy tailwinds.